AVRX Avalon Pharmaceuticals (MM)

GERMANTOWN, Md., May 2 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX) today announced that it is scheduled to release financial results for the first quarter of 2007, on Wednesday, May 9, 2007 after the close of the U.S. financial markets. The Company will host a conference call on Thursday, May 10, 2007 at 8:00 a.m. Eastern Daylight Savings Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet from the investor section of the Company's website or by dialing the numbers listed below. Conference Call Details: ------------------------ Dial-In: 866.202.3109 (U.S.) 617.213.8844 (International) Passcode: 34650950 Webcast: Please go to: http://www.avalonrx.com/, Investor Relations/ Upcoming Presentations, within 15 minutes prior to the call and select the webcast link. The conference call replay will be available through June 30, 2007 About Avalon Pharmaceuticals Avalon Pharmaceuticals is a biopharmaceutical company using its proprietary technology, AvalonRx(R), to discover and develop cancer therapeutics. Avalon has a lead product in Phase I clinical development (AVN944 - IMPDH inhibitor), as well as preclinical programs to discover inhibitors for the beta-catenin and aurora pathways now in late stage lead candidate optimization. Avalon also has discovery programs on modulators of survivin function and a drug discovery program targeting the MYC oncoprotein, one of the most important and previously intractable cancer targets. The company has value generating partnerships with Merck, MedImmune, Medarex, and Novartis. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Md. DATASOURCE: Avalon Pharmaceuticals CONTACT: David Muth, Executive Vice President and Chief Business Officer of Avalon Pharmaceuticals, +1-301-556-9900, Web site: http://www.avalonrx.com/

Copyright